Multiple Sclerosis

Latest News

Relapse Rates Lower With Ofatumumab in Multiple Sclerosis

Publish Date August 11, 2020

Annualized relapse rates are lower for patients with relapsing MS receiving anti-CD20 monoclonal antibody ofatumumab compared with teriflunomide.

Pandemic Causing Increased Anxiety Among MS Patients

Publish Date August 5, 2020

The COVID-19 pandemic is having an impact on the psychological health of patients with relapsing-remitting multiple sclerosis.

Relapses Linked to Accelerated Disability Progression in SPMS

Publish Date July 30, 2020

For patients with secondary progressive multiple sclerosis, relapses are associated with accelerated disability progression.

Chronic Neuropathic Pain in MS Reduced by Transcranial Direct Current Stimulation

Publish Date July 29, 2020

Repeated transcranial direct current stimulation over 5 days was able to reduce pain intensity in patients with chronic neuropathic pain due to multiple sclerosis.

Effects of BMI on B-Cells in Ocrelizumab-Treated Multiple Sclerosis

Publish Date July 16, 2020

Researchers confirmed the effectiveness of ocrelizumab in the treatment of relapsing-remitting and progressive MS, and found significant influence of BMI on B-cell repopulation.

Vitamin D Deficiency, Smoking Tied to a Worse Prognosis of Multiple Sclerosis

Publish Date July 15, 2020

Compromise of long-term cognitive function and neuronal integrity are associated with vitamin D deficiency and smoking in patients with MS.

Changes in Cerebral Hemodynamics in Patients with Multiple Sclerosis

Publish Date July 13, 2020

In addition to common cerebral hemodynamic changes, patients with MS were found to have reduced CVR when compared with healthy controls.

Complementary, Alternative Medicine Use Increasing for MS

Publish Date July 10, 2020

For people with multiple sclerosis, there has been an increase in use of complementary and alternative medicine between 2001 and 2018.

Safety of Alemtuzumab for MS During the COVID-19 Pandemic

Publish Date July 9, 2020

Patients with severe MS treated with alemtuzumab displayed milder and shorter symptoms of COVID-19.

Older Age, Obesity, Disability Tied to Severe COVID-19 in MS

Publish Date June 30, 2020

For patients with MS, age, obesity, and high Expanded Disability Severity Scale score are significantly associated with increased risk for severe COVID-19.